Enliven Therapeutics (ELVN) Balance Sheet: Assets & Liabilities

Enliven Therapeutics (ELVN) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Enliven Therapeutics reported total assets of $476.17M and total liabilities of $16.57M. Shareholders' equity was $459.60M, up 48.3% from $309.85M a year earlier. Total debt stood at $399.00K against $462.62M in cash and short-term investments, a net cash position of $462.22M. That puts debt-to-equity at 0.00, compared with 0.00 a year earlier.

Enliven Therapeutics Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Enliven Therapeutics, Inc. (ELVN) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Current Assets
Cash and Cash Equivalents	98.90	124.12	100.14	75.54	110.02	130.37	4.94	7.38	9.67
Short-Term Investments	363.73	189.32	153.01	0.00	0.00	40.52	23.97	0.00	0.00
Cash & Short-Term Investments	462.62	313.44	253.15	75.54	110.02	130.37	28.91	7.38	9.67
Accounts Receivable	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	12.26	4.69	13.00	2.22	0.65	0.06	1.72	0.32	0.55
Total Current Assets	474.88	318.13	266.15	77.75	110.67	130.59	30.62	7.71	10.22
Non-Current Assets
Property, Plant & Equipment (Net)	0.42	0.46	1.06	1.52	0.95	0.42	0.44	0.00	0.00
Long-Term Investments	0.00	0.00	0.00	0.05	0.00	0.00	0.09	0.00	0.00
Other Non-Current Assets	0.66	7.18	4.65	4.03	0.05	0.09	2.14	0.00	0.00
Total Non-Current Assets	1.29	7.63	5.72	5.55	2.66	0.44	2.67	0.00	0.00
Total Assets	476.17	325.76	271.87	83.30	113.33	131.00	33.30	7.71	10.22
Current Liabilities
Accounts Payable	2.16	1.34	0.53	3.44	2.52	0.81	1.66	0.91	0.43
Short-Term Debt	0.40	0.00	0.34	0.32	0.16	0.00	0.00	0.00	0.00
Accrued Liabilities	9.36	14.57	11.34	6.28	1.68	0.43	-	-	-
Deferred Revenue	0.00	0.00	0.00	5.51	0.00	0.00	0.00	0.00	0.00
Other Current Liabilities	0.35	14.57	25.03	1.64	0.37	0.14	2.54	0.92	0.40
Total Current Liabilities	16.57	15.92	25.89	9.72	5.75	1.48	4.20	1.83	0.83
Non-Current Liabilities
Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.66
Deferred Tax Liabilities	0.11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Non-Current Liabilities	0.00	0.00	0.07	0.66	0.71	0.08	0.18	32.19	0.00
Total Non-Current Liabilities	0.11	0.00	0.07	0.66	150.46	0.16	0.18	32.19	0.66
Total Liabilities	16.57	15.92	25.96	10.37	156.22	1.56	4.38	1.83	1.49
Stockholders' Equity
Common Stock	0.06	0.05	0.04	0.00	0.00	0.00	0.00	0.00	0.00
Retained Earnings	-347.17	-243.47	-154.45	-82.86	-45.20	-20.46	-54.75	-31.29	-19.95
Accumulated Other Comprehensive Income	0.33	0.06	0.14	-0.15	0.00	0.00	0.03	0.00	0.00
Additional Paid-in Capital	806.37	553.21	400.17	6.04	2.31	180.53	5.87	4.97	4.42
Shares Outstanding	59.44	48.94	41.29	41.10	41.10	-	-	-	-
Total Stockholders' Equity	459.60	309.85	245.91	72.92	-42.89	129.45	-48.85	-26.32	-15.53
Total Liabilities & Equity	476.17	325.76	271.87	83.30	113.33	90.84	33.30	7.71	10.22

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Enliven Therapeutics Balance Sheet

How much debt does Enliven Therapeutics have?

Enliven Therapeutics had total debt of $399.00K as of Dec 31, 2025, against $462.62M in cash and short-term investments. Its debt-to-equity ratio was 0.00. Total debt was $0.00 a year earlier.

What are Enliven Therapeutics's total assets?

Enliven Therapeutics reported total assets of $476.17M as of Dec 31, 2025, up 46.2% from $325.76M a year earlier. Total liabilities were $16.57M.

What is Enliven Therapeutics's shareholders' equity?

Enliven Therapeutics's shareholders' equity was $459.60M as of Dec 31, 2025, or about $7.73 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition